Sugi Predict

Sugi Predict / Targets / LRRK2

LRRK2

Leucine-rich repeat serine/threonine-protein kinase 2 · Q5S007 · LRRK2 on Sugi Atlas →

232,361 patent compounds predicted against LRRK2, 118,053 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL82445 SCHEMBL82445 0.56 9/20
SCHEMBL68129 SCHEMBL68129 0.51 6/20
SCHEMBL98437 SCHEMBL98437 0.50 6/20
SCHEMBL61206 SCHEMBL61206 0.33 6/20
SCHEMBL78242 SCHEMBL78242 0.56 4/20
SCHEMBL74296 SCHEMBL74296 0.47 4/20
Isatin Isatin (SCHEMBL34016) 0.67 3/20
SCHEMBL98881 SCHEMBL98881 0.57 3/20
SCHEMBL100736 SCHEMBL100736 0.50 3/20
SCHEMBL41122 SCHEMBL41122 0.49 3/20
SCHEMBL100040 SCHEMBL100040 0.48 3/20
SCHEMBL100903 SCHEMBL100903 0.47 3/20
SCHEMBL101518 SCHEMBL101518 0.45 3/20
SCHEMBL42384 SCHEMBL42384 0.43 3/20
SCHEMBL99210 SCHEMBL99210 0.43 3/20
SCHEMBL101240 SCHEMBL101240 0.41 3/20
SCHEMBL48258 SCHEMBL48258 0.41 3/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 2/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 2/20
Adenine Adenine (SCHEMBL8111) 1.00 2/20

Clinical trials — most relevant to LRRK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) PHASE2ACTIVE_NOT_RECRUITING
Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease PHASE2NOT_YET_RECRUITING
PPMI Tau PET Imaging PHASE2COMPLETED
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD PHASE2ACTIVE_NOT_RECRUITING
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers EARLY_PHASE1COMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease nanCOMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
A Longitudinal Study in Parkinson's Disease (PD) Patients nanUNKNOWN
Chinese PD-LRRK2 Registry nanRECRUITING
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation nanRECRUITING
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease nanCOMPLETED
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2) nanCOMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
FoxBioNet: ECV (Extracellular Vesicle) 004 nanCOMPLETED
Effect of Ketone Esters in Parkinson's Disease nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Fox BioNet Project: LRRK2-002 nanCOMPLETED
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort nanRECRUITING
The Effect of Immersion in Virtual Reality on Upper Limb Functionality in Subjects With Parkinson's Disease: Randomized Clinical Trial nanUNKNOWN
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease nanCOMPLETED
Age Dependents Benefits of Virtual Reality Rehabilitation nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
The Relationship Between Homocysteine and Manifestation of Parkinson's Disease Patients nanNOT_YET_RECRUITING
LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease nanCOMPLETED
LIPAD - LRRK2 International Parkinson's Disease Study nanUNKNOWN
miRNAs Profiling in Parkinson's Disease nanCOMPLETED
Genetic Analysis of Parkinson's Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LRRK2 binder may also engage these)

ProteinNameSimilarity
Q5S006 — 0.997 Q5S006 →
Q9DE14 — 0.992 Q9DE14 →
ATR Serine/threonine-protein kinase ATR 0.990 landscape →
Q21920 — 0.990 Q21920 →
Q9JKK8 — 0.989 Q9JKK8 →
O65020 — 0.988 O65020 →
O14715 — 0.988 O14715 →
O74447 — 0.988 O74447 →
Q9LYZ7 — 0.988 Q9LYZ7 →
P97313 — 0.988 P97313 →
Q9FKS4 — 0.988 Q9FKS4 →
Q8BH53 — 0.988 Q8BH53 →
Q9DEI1 — 0.988 Q9DEI1 →
Q99666 — 0.987 Q99666 →
Q6CAD2 — 0.987 Q6CAD2 →
G5ED39 — 0.987 G5ED39 →
P32333 — 0.987 P32333 →
Q8BKX6 — 0.987 Q8BKX6 →
Q5MNV8 — 0.987 Q5MNV8 →
Q09562 — 0.987 Q09562 →
Q751Y8 — 0.987 Q751Y8 →
O15050 — 0.987 O15050 →
Q76K24 — 0.986 Q76K24 →
Q5ICL9 — 0.986 Q5ICL9 →
F4I893 — 0.986 F4I893 →
P45964 — 0.986 P45964 →
PI4KA Phosphatidylinositol 4-kinase alpha 0.986 landscape →
Q9R1W3 — 0.986 Q9R1W3 →
A1Z8X3 — 0.986 A1Z8X3 →
Q7Z5J8 — 0.986 Q7Z5J8 →